Legal & General Group PLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Legal & General Group PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.04 - $9.66 $4,463 - $7,138	739 Added 17.08%	5,066 $38,000
Q2 2022 Aug 22, 2022	BUY	$4.99 - $8.96 $8,263 - $14,837	1,656 Added 62.0%	4,327 $27,000
Q2 2021 Aug 12, 2021	SELL	$7.82 - $9.23 $6,701 - $7,910	-857 Reduced 24.29%	2,671 $23,000
Q1 2021 May 17, 2021	SELL	$8.44 - $12.66 $1,190 - $1,785	-141 Reduced 3.84%	3,528 $31,000
Q4 2020 Feb 12, 2021	BUY	$7.98 - $12.29 $2,769 - $4,264	347 Added 10.45%	3,669 $45,000

Q3 2020 Nov 13, 2020	SELL	$7.96 - $12.42 $5,070 - $7,911	-637 Reduced 16.09%	3,322 $27,000
Q2 2020 Aug 14, 2020	SELL	$5.4 - $13.37 $183 - $454	-34 Reduced 0.85%	3,959 $38,000
Q1 2020 May 14, 2020	SELL	$4.91 - $14.7 $4,070 - $12,186	-829 Reduced 17.19%	3,993 $27,000
Q4 2019 Feb 13, 2020	BUY	$9.77 - $15.66 $8,890 - $14,250	910 Added 23.26%	4,822 $72,000
Q2 2019 Aug 14, 2019	BUY	$9.54 - $14.96 $37,320 - $58,523	3,912 New	3,912 $41,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $492M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.